低剂量化疗治疗神经母细胞瘤的研究进展  

The progress of low-dose chemotherapy in neuroblastoma

作　　者：高琳(综述)[1] 代辰飞(综述)[1] 闻德亮(审校)[1] 

机构地区：[1]中国医科大学,沈阳110001

出　　处：《国际儿科学杂志》2012年第3期301-303,共3页International Journal of Pediatrics

摘　　要：近年来，低剂量化疗在恶性肿瘤的治疗中备受关注，这种化疗模式除了能有效抗血管生成外，也可以在很大程度上减少化疗的不良反应，如骨髓抑制、肝肾功能损害、消化道反应及耐药性产生等，从而增加患者的依从性，提高生活质量，延长生存时问。目前化疗在神经母细胞瘤的治疗中仍起着关键作用，特别是低剂量化疗，能最大限度保护自身免疫功能，减少对患儿的损伤。Low-dose chemotherapy is concerned in treating malignant tumor in recent years. The low- dose, metronomic chemotherapy is not only effective in antiangiogenic, but also avoid chemotherapy side effects, such as suppression of bone marrow, dysfunction of liver and kidney, gastrointestinal reaction and drug resist- ance. Thereby it can increase patient compliance, improve life quality and prolong survival time. Currently chemotherapy in neuroblastoma still plays a key role, especially low-dose chemotherapy, which can protect self-immune function and reduce the physical injury in children.

关 键 词：低剂量化疗 神经母细胞瘤 抗血管生成 治疗 研究进展 

分 类 号：R730.5[医药卫生—肿瘤]